Respiratory Syncytial Virus in Older Adults: Understanding Risk, Diagnosis, and Evolving Prevention Strategies

Learn about risk factors for respiratory syncytial virus among adults, the need for a vaccination strategy in this population, and the evolving clinical studies on vaccine strategies for older adults.
Spencer Durham Headshot
Spencer H. Durham, PharmD, BCPS, BCIDP
person default
Stefan Gravenstein, MD, MPH
Barbara Resnick, PhD, CRNP
Format: Microsoft PowerPoint (.ppt)
File Size: 507 KB
Released: June 25, 2021


This activity is provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Educational grant provided by:
Janssen Therapeutics, Division of Janssen Products, LP

Related Content

Expert commentary on updates in vaccine development for RSV, from Dr Angela Branche and Clinical Care Options (CCO)

person default Angela Branche, MD Released: April 7, 2022

Expert commentary on addressing barriers to vaccine uptake in older individuals, from Dr Barbara Resnick and Clinical Care Options (CCO)

Barbara Resnick, PhD, CRNP Released: January 12, 2022

Expert commentary on current vaccine candidates for RSV, from Dr. Spencer H. Durham and Clinical Care Options (CCO)

Spencer Durham Headshot Spencer H. Durham, PharmD, BCPS, BCIDP Released: October 28, 2021

From Elliott Bosco, PharmD, and Clinical Care Options (CCO), expert commentary on the risks and costs of RSV to older adults in the United States

person default Elliott Bosco, PharmD, PhD Released: August 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings